Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
3BP2-deficient mice are osteoporotic with impaired osteoblast and osteoclast functions
Noam Levaot, … , Ernst Reichenberger, Robert Rottapel
Noam Levaot, … , Ernst Reichenberger, Robert Rottapel
Published July 18, 2011
Citation Information: J Clin Invest. 2011;121(8):3244-3257. https://doi.org/10.1172/JCI45843.
View: Text | PDF
Research Article Bone biology

3BP2-deficient mice are osteoporotic with impaired osteoblast and osteoclast functions

  • Text
  • PDF
Abstract

A fine balance between bone resorption by osteoclasts and bone formation by osteoblasts maintains bone homeostasis. In patients with cherubism, gain-of-function mutations in 3BP2, which is encoded by SH3-domain binding protein 2 (SH3BP2), cause cystic lesions with activated osteoclasts that lead to craniofacial abnormalities. However, little is known about the function of wild-type 3BP2 in regulating bone homeostasis. Here we have shown that 3BP2 is required for the normal function of both osteoblasts and osteoclasts. Initial analysis showed that Sh3bp2–/–mice developed osteoporosis as a result of reduced bone formation despite the fact that bone resorption was impaired. We demonstrated using reciprocal bone marrow chimeras, a cell-intrinsic defect of the osteoblast and osteoclast compartments in vivo. Further, Sh3bp2–/– osteoblasts failed to mature and form mineralized nodules in vitro, while Sh3bp2–/– osteoclasts spread poorly and were unable to effectively degrade dentine matrix in vitro. Finally, we showed that 3BP2 was required for Abl activation in osteoblasts and Src activation in osteoclasts, and demonstrated that the in vitro defect of each cell type was restored by the respective expression of activated forms of these kinases. These findings reveal an unanticipated role for the 3BP2 adapter protein in osteoblast function and in coordinating bone homeostatic signals in both osteoclast and osteoblast lineages.

Authors

Noam Levaot, Paul D. Simoncic, Ioannis D. Dimitriou, Andrew Scotter, Jose La Rose, Adeline H.M. Ng, Thomas L. Willett, Chiachien J. Wang, Salima Janmohamed, Marc Grynpas, Ernst Reichenberger, Robert Rottapel

×

Figure 6

Impaired osteoblast maturation in Sh3bp2–/– mice.

Options: View larger image (or click on image) Download as PowerPoint
Impaired osteoblast maturation in Sh3bp2–/– mice.
   
(A) In vitro osteo...
(A) In vitro osteoblast maturation assay. Bone marrow–derived stromal cells were cultured for 21 days and stained for ALP after 7, 14, or 21 days of culture. (B) Quantification of ALP activity after 14 days of culture. n = 9; *P < 0.05. (C) Collagen I deposition as determined by picric acid staining after 7, 14, and 21 days of culture. (D) Mineralized nodule formation as determined by von Kossa staining after 7, 14, and 21 days of culture. (E) FACS analysis of Sca-1+CD29+CD45–CD11b– skeletal stem cells from 12- to 13-week-old wild-type or Sh3bp2–/– mice. n = 7. (F) Quantification of CFU-F from wild-type and Sh3bp2–/– bone marrow–derived adherent cells cultured for 2 weeks. n = 12. (G) ALP staining of CFU-F cultured for 28 days. (H) Quantification of CFU-Ob from G. n = 6; *P < 0.05. (I) Immunofluorescence staining for Runx2 (red) or nuclei (DAPI). Original magnification, ×10. (J) Decreased mineralized nodules of Sh3bp2–/– calvarial-derived osteoblasts cultured for 21 days and stained with Alizarin red (K). Quantification of calvarial osteoblast mineralized nodules in I. n = 6; *P < 0.01. (L) Quantitative PCR of runx2, osterix, and osteocalcin transcript levels in calvarial osteoblasts cultured for 21 days. n = 3; *P < 0.05. Data are presented as mean ± SEM.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts